BRAF and cancer: More than 29 kinds of kinase inhibitors have been developed to treat various cancers, including the BRAF inhibitors vemurafenib and dabrafenib of ERK signaling and the MEK (Mitogen-activated protein kinase kinase) inhibitor trametinib [24–26].